On 7 January 2025, a magnitude 6.8 earthquake, which struck at a depth of 10 km, hit Tingri County, Shigatse City in Tibet, causing heavy casualties and house damages. Caring about the disaster, China Medical System Holdings Limited (“CMS”) has made proactive disaster relief efforts through its wholly-owned subsidiary, Tibet Kangzhe Pharmaceutical Development Co., Ltd. On January 9th, it donated relief supplies worth nearly RMB 0.5 million to the earthquake-stricken area through Tibet Development Philanthropic Foundation, including disinfectant, military coats, cotton quilts, and cotton jackets, etc. Moreover, on January 13th, it donated a special fund of RMB2 million to Tibet Charity Federation for post-disaster resettlement and reconstruction, to further help the disaster area to overcome the difficulties sooner. Join hands to fight the disaster, and pray for peace and safety. CMS wishes the earthquake-stricken area in Shigatse, Tibet rebuild their homes as earlier as possible.
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party. As the second oral therapy approved […]
On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the “Authorization Term”). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, […]
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D005 injection (“CMS-D005”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 27 November 2024. The NMPA grants the Group consent to conduct a clinical trial to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CMS-D005 in healthy and overweight/obese adult subjects in China. CMS-D005 CMS-D005 is a highly active and selective dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Activating glucagon-like peptide-1 (GLP-1) can reduce food intake through central appetite suppression and inhibit gastric emptying to increase satiety to achieve weight loss. Activating GLP-1R can enhance secretion of glucose-dependent insulin and inhibit secretion of glucagon to lower blood glucagon[1], while activating glucagon (GCG) can promote fat catabolism and enhance fat loss, […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 4 November 2024, the New Drug Application (NDA) of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been approved by the Pharmacy & Poisons Board of Hong Kong (PPBHK). The certificate of drug/product registration was obtained on 5 November 2024. The Product is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. About Ruxolitinib Cream Ruxolitinib cream (Opzelura®), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, and is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura®) is also approved in the […]
Recently, Healthcare Executive (“E药经理人”), in collaboration with a leading independent corporate social responsibility consulting agency in China, released the results of 2024 “Chinese Pharmaceutical Listed Companies ESG Competitiveness” series ranking. The ranking aims to recognize Chinese pharmaceutical companies that serve as benchmarks in various aspects of ESG management. By virtue of its continuous efforts in sustainable development and low-carbon initiatives, China Medical System (“CMS” or the “Group”) has been selected into the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness (Mid-cap Stocks)” ranking for three consecutive years, and has also been included in the inaugural “Top 10 Low-Carbon Pioneers of Chinese Pharmaceutical Listed Companies” ranking. As an active practitioner of the sustainable development concept, CMS steadily responds to the United Nations Sustainable Development Goals, and promotes the deep integration of ESG governance with its macro strategies and business operations. With adherence to high standards of business ethics in its operations, the Group has established a scientific and effective risk identification […]
China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the “Hong Kong and Macau Medicine and Equipment Connect” policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in […]
On September 27, the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association released the “2024 Shenzhen Top 500 Enterprises” list. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 149th, by virtue of its outstanding operational performance, social contributions, etc. Additionally, Shenzhen Kangzhe was also included in the “2024 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2024 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500.” CMS has been deeply rooted in the Chinese pharmaceutical market for over 30 years, developing into a platform company linking pharmaceutical innovation and commercialization. Shenzhen Kangzhe’s inclusion in the “Shenzhen Top 500 Enterprises” for the fourth time not only affirms the Group’s long-term strategic focus on specialty therapeutic fields and its success in providing differentiated products […]
On September 20, 2024, China Medical System (“CMS” or the “Group”) presented its innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) at the 24th Congress of Gastroenterology China in 2024 (“CGC 2024”). This congress brought together numerous domestic scholars and clinical experts in the field of gastroenterology to discuss key topics and advancements in gastroenterology disease research, serving as an important platform for promoting progress in the diagnosis and treatment of gastroenterology diseases in China. CMS develops innovative products with a focus on medical values and clinical needs, striving to provide effective and affordable therapeutic solutions for patients. The innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) is indicated to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy, which not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving […]
